Wanbury Ltd

The investor presentation from Wanbury Limited, dated July 1, 2026, provided an overview of the company's audited financial results for the quarter and year ended March 31, 2026. Management reported a successful turnaround to growth momentum, highlighting global market leadership in key products such as Metformin and Sertraline. The presentation detailed a significant operational and financial turnaround over the past three years, with a focus on building new growth drivers in the API business. Management noted a de-risked balance sheet with a moderate leverage ratio of approximately 2X Debt/EBITDA. The company achieved its highest-ever operational EBITDA of ₹108 crore in FY26 and reported an 8% year-on-year revenue growth to ₹650 crore. The formulations business reached break-even profitability in FY26, supported by new product launches and an improved go-to-market strategy. The presentation emphasized the company's commitment to operational efficiencies and regulatory compliance.

Management emphasized growth and operational improvements throughout the presentation.